Maximus, Inc. (NYSE:MMS – Get Rating) was the recipient of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 1,310,000 shares, a decline of 23.8% from the March 31st total of 1,720,000 shares. Currently, 2.1% of the shares of the company are sold short. Based on an average daily volume of 413,800 shares, the days-to-cover ratio is currently 3.2 days.
A number of hedge funds have recently bought and sold shares of the stock. Victory Capital Management Inc. lifted its holdings in Maximus by 9.1% in the fourth quarter. Victory Capital Management Inc. now owns 4,604,112 shares of the health services provider’s stock worth $366,810,000 after purchasing an additional 383,810 shares during the period. Alliancebernstein L.P. lifted its holdings in Maximus by 6.2% in the 4th quarter. Alliancebernstein L.P. now owns 3,339,698 shares of the health services provider’s stock valued at $266,074,000 after acquiring an additional 193,816 shares during the last quarter. Mackenzie Financial Corp boosted its position in shares of Maximus by 3.1% during the 4th quarter. Mackenzie Financial Corp now owns 2,679,821 shares of the health services provider’s stock valued at $213,501,000 after purchasing an additional 81,037 shares in the last quarter. Pictet Asset Management SA grew its stake in shares of Maximus by 1.6% in the 4th quarter. Pictet Asset Management SA now owns 1,439,782 shares of the health services provider’s stock worth $114,707,000 after purchasing an additional 22,925 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Maximus by 0.5% in the 3rd quarter. Janus Henderson Group PLC now owns 1,248,378 shares of the health services provider’s stock worth $103,865,000 after purchasing an additional 5,912 shares in the last quarter. 93.54% of the stock is owned by institutional investors and hedge funds.
MMS has been the subject of a number of research reports. StockNews.com initiated coverage on shares of Maximus in a report on Thursday, March 31st. They issued a “hold” rating for the company. Zacks Investment Research downgraded shares of Maximus from a “strong-buy” rating to a “hold” rating and set a $86.00 price target for the company. in a report on Thursday, April 7th.
Maximus (NYSE:MMS – Get Rating) last announced its quarterly earnings results on Thursday, February 3rd. The health services provider reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.80 by $0.32. The company had revenue of $1.15 billion during the quarter, compared to the consensus estimate of $1.10 billion. Maximus had a net margin of 6.29% and a return on equity of 22.04%. The company’s revenue for the quarter was up 21.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.03 earnings per share. Analysts predict that Maximus will post 5.23 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 31st. Investors of record on Friday, May 13th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 1.54%. The ex-dividend date is Thursday, May 12th. Maximus’s payout ratio is currently 25.00%.
About Maximus (Get Rating)
Maximus, Inc provides business process services (BPS) to government health and human services programs. It operates through three segments: U.S. Services, U.S. Federal Services, and Outside the U.S. The U.S. Services segment offers various BPS solutions, such as program administration, appeals and assessments, and related consulting works for U.S.
- Get a free copy of the StockNews.com research report on Maximus (MMS)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.